{"url_path":"/sec/rigl/8-k/2026-06-17/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 Completion of Acquisition or Disposition of Assets.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1034842/0001034842-26-000043-index.html","accession_number":"0001034842-26-000043","cik":"0001034842","ticker":"RIGL","issuer_name":"RIGEL PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1034842/0001034842-26-000043-index.html","primary_entity_key":"0001034842","primary_entity_name":"RIGEL PHARMACEUTICALS INC"},"word_count":191,"has_tables":true,"body_markdown":"Item 2.01.    Completion of Acquisition or Disposition of Assets.\n\nAs previously disclosed in the Current Report on Form 8-K filed by Rigel Pharmaceuticals, Inc. (the “Company”) on May 12, 2026, the Company entered into a License Agreement (the “License Agreement”) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the “Licensors”), pursuant to which the Licensors granted the Company exclusive, global rights to develop, manufacture and commercialize VEPPANU™ (vepdegestrant) and related products worldwide.\n\nFollowing the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of the other closing conditions under the License Agreement, the License Agreement became effective and the transactions contemplated thereby were completed. In connection therewith, the Company paid the Licensors a one-time upfront payment of $70.0 million.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: June 17, 2026\nRIGEL PHARMACEUTICALS, INC.\n\nBy:/s/ Raymond J. Furey\n\nRaymond J. Furey\n\nExecutive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary"}